Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Ingeniería de partículas y cristales para fluidos supercríticos y mejora de la biodisponibilidad

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20161128001
Publicado:
05/01/2017
Caducidad:
05/01/2018
Resumen:
Una compañía farmacéutica británica está especializada en aplicaciones de ingeniería de partículas y cristales para fluidos supercríticos que permiten diseñar terapias más eficaces. El proceso de fluidos supercríticos de un solo paso tiene ventajas sobre las tecnologías convencionales de reducción del tamaño de partículas en el desarrollo de productos farmacéuticos: manipulación del tamaño de partículas y características de superficie para diseñar cristales y partículas más solubles o descubrimiento de nuevas formas polimórficas de estado sólido que no pueden descubrirse con otros métodos convencionales. La empresa busca organismos del sector farmacéutico que requieran técnicas alternativas para mejorar la solubilidad y biodisponibilidad de nuevas entidades químicas. El objetivo es establecer acuerdos de licencia, cooperación técnica o investigación.

Details

Tittle:
Supercritical fluid crystal and particle engineering to improve bioavailability
Summary:
A UK pharmaceutical SME specialises in applications of super-critical fluid crystal and particle engineering technology for the design of more effective therapies. The company is looking for organisations working in the pharmaceutical sector who require alternative techniques to improve solubility and bioavailability of new chemical entities (NCEs). The partnerships may be license agreements, technical cooperation agreements or research cooperation agreements.
Description:
It has been reported in the scientific literature that up to 70% of NCEs and up to 40% of currently marketed drugs exhibit poor solubility, leading to low bioavailability and resulting in poor pharmacokinetic profiles and therapeutic efficacy. Challenges of these poorly soluble drugs can be addressed through particle engineering, identifying new solid state forms and generating combination particles that incorporate the active pharmaceutical ingredients (API) with enhancer agents that will aid dissolution.
A UK-based SME specialises in applications of the latest supercritical fluid (SCF) crystal and particle engineering technology to pharmaceutical product development. The team includes leading experts, who have helped design the world´s first SCF-based medicine, an inhaled treatment for migraine, which is currently awaiting final FDA review.
The single-step SCF process has intrinsic advantages over conventional size reduction technologies in the development of oral pharmaceutical products. These include the manipulation of particle size and surface area characteristics to engineer crystals and particles with improved solubility; finding new polymorphic solid state forms that cannot be found using other traditional screening methods with higher dissolution rates and generating combination particles that incorporate enhancer agents with the API to aid the rate of dissolution.

They are looking to partner with SMEs, research and development organisations, universities, not-for-profit companies or foundations and large companies from the pharmaceutical industry. Partners who are experiencing drug development challenges and are looking for alternative technologies to improve the solubility and bioavailability of small molecules and NCEs. The expected partnerships may take the form of license agreements, technical cooperation agreements or research cooperation agreements.


Advantages and Innovations:
Supercritical fluid technology (SCF) is innovative because the characteristics of the particle can be fine-tuned right from the outset; modifying the size, shape, morphology and surface properties. In comparison with microionisation, SCF processed powders exhibited a 3-fold improvement in bioavailability.
The process is FDA approved, highly reproducible and readily scalable. The team also has vast experience in oral dosage formulations.
Stage of Development:
Already on the market
IPs:
Exclusive rights

Partner sought

Type and Role of Partner Sought:
The UK based company are looking to partner with SMEs, research and development organisations, universities, not-for-profit companies or foundations and large companies from the pharmaceutical industry. Partners who are experiencing drug development challenges and are looking for alternative technologies to improve the solubility and bioavailability of small molecules and NCEs are sought.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
05005 Micro y nanotecnología
06004 Micro y nanotecnología relacionada con las ciencias biológicas
06002008 Microbiología
03004007 Pharmaceutics
06001013 Tecnología médica / ingeniería biomédica